Literature DB >> 16485880

The position not the presence of the halogen in corticosteroids influences potency and side effects.

Joseph Bikowski1, Radhakrishnan Pillai, Braham Shroot.   

Abstract

Many topical corticosteroids currently on the market contain a halogen substitution at the C6, C9, or the side-chain C21 position of the corticosteroid skeleton. These modifications have enhanced the efficacy of corticosteroids as compared to hydrocortisone as topical anti-inflammatory agents, but have often increased side effects such as skin atrophy, adrenal suppression, and telangiectasia. These side effects have been attributed to the presence of halogens in the corticosteroid molecule and have raised concerns regarding the safety of all halogenated corticosteroids. In this review, we assert that it is the position and nature of the halogen atom(s) in the corticosteroid molecule that determine potency/toxicity, rather than their mere presence. A greater understanding of the role of halogenation in determining corticosteroid potency and side effects will clarify why all halogenated steroids are not the same.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16485880

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  7 in total

1.  Structural Analysis of the Glucocorticoid Receptor Ligand-Binding Domain in Complex with Triamcinolone Acetonide and a Fragment of the Atypical Coregulator, Small Heterodimer Partner.

Authors:  Emily R Weikum; C Denise Okafor; Emma H D'Agostino; Jennifer K Colucci; Eric A Ortlund
Journal:  Mol Pharmacol       Date:  2017-04-10       Impact factor: 4.436

2.  To Study the Efficacy of Difluprednate Ophthalmic Emulsion and Prednisolone Acetate Ophthalmic Suspension on Post-operative Inflammation in Cataract Surgery.

Authors:  Punita Garg; Nupur Tuteja; Shazia Qayum
Journal:  J Clin Diagn Res       Date:  2016-12-01

3.  The role of difluprednate ophthalmic emulsion in clinical practice.

Authors:  Karim N Jamal; David G Callanan
Journal:  Clin Ophthalmol       Date:  2009-06-29

4.  A Comprehensive Review of Clocortolone Pivalate 0.1% Cream: Structural Development, Formulation Characteristics, and Studies Supporting Treatment of Corticosteroid-responsive Dermatoses.

Authors:  James Q Del Rosso; Leon Kircik
Journal:  J Clin Aesthet Dermatol       Date:  2012-07

5.  Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated.

Authors:  Harsha H Kariyawasam; Glenis K Scadding
Journal:  J Asthma Allergy       Date:  2010-06-21

6.  Understanding the correlation between structure and dynamics of clocortolone pivalate by solid state NMR measurement.

Authors:  Krishna Kishor Dey; Shovanlal Gayen; Manasi Ghosh
Journal:  RSC Adv       Date:  2020-01-27       Impact factor: 4.036

7.  The treatment of vasomotor rhinitis with intranasal corticosteroids.

Authors:  Eli O Meltzer
Journal:  World Allergy Organ J       Date:  2009-08-15       Impact factor: 4.084

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.